(Reuters) – Pharmaceutical company CordenPharma has extended its agreement with Moderna Inc to supply large volumes of lipids used to produce Moderna’s COVID-19 vaccine candidate.
The expanded agreement will be effective immediately to help meet Moderna’s increasing demand over the coming months, it said in a statement.
“This expansion will increase supply of lipid excipients used to manufacture our mRNA products,” Moderna’s chief technical operations and quality officer, Juan Andres, said.
(Reporting by Shubham Kalia in Bengaluru; Editing by Saumyadeb Chakrabarty)
